Author: Nina Isoherranen, PhD on May 10, 2019
In January 2017 Clinical and Translational Science launched the Brief Reports article category. This article type was intended for publication of short-format papers that describe significant novel research findings in translational sciences. During the first four months of 2019 we have seen authors take advantage of this article category with three exciting brief reports published this year.
In the first of these brief reports, published in February, Schuck et al. describe their analysis of use of dose titration as a therapeutic individualization strategy for FDA approved drugs. The Brief Report is based on a systematic analysis of labeling of all NMEs approved between 2013-2017, including evaluation on how often titration to effect was used in pivotal clinical trials. The authors found that response-guided titration was used for a minority of drugs for which it might be useful, and the authors suggest careful consideration of whether response-guided titration could be used to reduce interpatient variability.
In the April issue of CTS, Hardiansyah and Ng describe the development of a novel Quantitative Systems Pharmacology (QSP) model of CAR T-cell therapy that links the relationship between the growth of the CAR T-cells and the pro-inflammatory cytokines associated with CAR T-cell therapy in patients with chronic lymphocytic leukemia. The Brief Report describes how QSP modeling could be used to show that the inflammatory cytokine elevation was most closely associated with baseline disease burden rather than the administered dose of the CAR T-cells.
The third Brief Report published this year by Juif et al. describes the clinical OATP1B1/OATP1B3 mediated drug-drug interaction between single dose rifampicin and intravenously administered clazosentan, a selective endothelin A receptor antagonist. It clearly describes the significant decrease in clazosentan clearance and Vss as a result of coadministration of rifampicin and the resulting changes in clazosentan exposure. The results of the study led to the prediction that clazosentan will be susceptible to OATP1B1/OATP1B3 mediated drug interactions.
These three Brief Reports are wonderful examples of how exciting findings in translational sciences can be communicated in a shorter format than a traditional journal article. These reports inspire the expansion of Brief Reports for rapid communication of novel, impactful findings. Please submit yours today!
The comment feature is locked by administrator.